Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

Exclusion Criteria

• •Subject currently breast-feeding.
• •Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial vaccination.
• •Planned participation in another clinical trial during the present trial period.
• •Prior participation in the Phase I trial of FLU INTERPAN (PER.C6) vaccine (study GCE01).
• •Congenital or history of acquired immunodeficiency, or immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months.
• •Systemic corticosteroid therapy as except the use of topical or inhalant corticosteroids
• •Systemic hypersensitivity to egg proteins, chicken proteins, or to any of the vaccine components, or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances.
• •Chronic illness at a stage that could interfere with trial conduct or completion (chronic illness may include, but is not limited to, cardiac, renal or auto-immune disorders, or diabetes).
• •Receipt of blood or blood-derived products in the 3 months preceding vaccination.
• •Receipt of any vaccination in the 4 weeks preceding vaccination, or planned receipt of any vaccination in the 4 weeks following the trial vaccination.
• •History of influenza infection (confirmed either clinically, serologically or microbiologically) within the 6 months preceding vaccination.
• •Previous vaccination against influenza (in the 6 months preceding the trial vaccination).
• •Planned receipt of any other 2007-2008 influenza vaccine.
• •Thrombocytopenia or bleeding disorder contraindicating intramuscular (IM) vaccination.
• •Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.
• •History of Guillain-Barré syndrome
• •Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures
• •Any other condition which in the opinion of the investigator would pose a health risk to the participant or interfere with the evaluation of the vaccine.